Back to search
GERD - PPI Non-responders
Clinical trial pipeline · Data from ClinicalTrials.gov
See which GERD - PPI Non-responders trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which GERD - PPI Non-responders trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
Gastroesophageal reflux disease (GERD) is a very common condition affecting up to 30% of adults. To date, therapy consists of powerful acid suppression with pro…
The prevalence of GERD is estimated to be as high as 20% in the US, and up to 50% remain symptomatic on proton pump inhibitor (PPI) therapy. The clinical approa…